Point72 Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$985K Buy
+238,435
New +$808K ﹤0.01% 2796
2026
Q1
– Sell
-654,211
Closed -$2.53M – 4402
2025
Q4
$2.68M Buy
+654,211
New +$3.24M ﹤0.01% 2302
2024
Q2
– Sell
-400,700
Closed -$3.99M – 2369
2024
Q1
$3.99M Sell
400,700
-1,069,500
-73% -$11.9M 0.01% 1044
2023
Q4
$14.5M Buy
1,470,200
+1,332,700
+969% +$9.5M 0.04% 553
2023
Q3
$1.05M Buy
+137,500
New +$1.37M ﹤0.01% 1313

Other funds holding RXRX

Point72 Asset Management's RXRX Position: Q3 2026 in Review

Point72 Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 238,435 shares worth $985K. The stake represents ﹤0.01% of the portfolio and ranks #2796 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in RXRX as recently as Q4 2025.

Point72 Asset Management first reported a position in RXRX in Q3 2023 and has held it in 5 quarters since. The position peaked at $14.5M in Q4 2023. 353 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Point72 Asset Management held 238,435 shares of Recursion Pharmaceuticals worth $985K as of Q3 2026.
  • Recursion Pharmaceuticals was a new Point72 Asset Management position in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q3 2026, its #2796 holding.
  • Point72 Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
  • Point72 Asset Management's Recursion Pharmaceuticals position peaked at $14.5M in Q4 2023.
  • 353 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.